CHAD Therapeutics Launches Advanced New Oxygen Conserver and Next-Generation Oxygen Transfilling System at Medtrade Show in Las Vegas.CHATSWORTH, Calif. -- CHAD Therapeutics, Inc. (AMEX AMEX See: American Stock Exchange :CTU CTU Colorado Technical University CTU Czech Technical University in Prague CTU Counter Terrorist Unit CTU Clinical Trials Unit CTU Catholic Theological Union CTU Chicago Teachers Union CTU Computer Training Unit CTU Control Unit ) today announced the launch of an advanced pneumatic oxygen conserver and its next-generation oxygen transfilling system at the Medtrade show in Las Vegas Las Vegas (läs vā`gəs), city (1990 pop. 258,295), seat of Clark co., S Nev.; inc. 1911. It is the largest city in Nevada and the center of one of the fastest-growing urban areas in the United States. . CHAD's advanced BONSAI(TM) pneumatic conserver is an important addition to the Company's extensive line of oxygen conserving devices. "With its sleek, lightweight design The introduction to this article provides insufficient context for those unfamiliar with the subject matter. Please help [ improve the introduction] to meet Wikipedia's layout standards. You can discuss the issue on the talk page. (less than 10 ounces), conserving ratio of up to 6:1, eight settings, and an adjustable continuous flow feature, BONSAI reinforces CHAD's longstanding leadership in the oxygen conserver market. A pneumatic conserving device that offers a 6:1 savings ratio while ensuring adequate oxygen saturation oxygen saturation sO2 The O2 concentration of blood expressed as a ratio of its total O2-carrying capacity; the OS is a measure of the utilization of O2 transport capacity; sO2 for patients is a groundbreaking achievement," said President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Earl Yager. CHAD currently expects to receive FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance to market and be able to begin shipping this new device in May. Yager continued, "CHAD's next-generation oxygen transfilling system, the OMNI OMNI Omnidirectional OMNI Organising Medical Networked Information OMNI Opportunities for Micronutrient Interventions Project OMNI Operating Missions as a Node on the Internet (NASA networking project) line, is a significant upgrade to CHAD's pioneering TOTAL O2([R]) Home Oxygen Delivery System that meets the needs of a broader range of oxygen patients than ever before and gives homecare providers a powerful tool to reduce operating costs and take advantage of the new Medicare transfilling reimbursement category that took effect on January 1, 2007." The OMNI 2 is designed for the specific requirements of pediatric patients. The OMNI 5 offers increased oxygen delivery of up to 5 liters per minute. In addition to providing stationary oxygen, both devices can also refill a wide variety of portable oxygen cylinders in the patient's home, thus eliminating the cost for the homecare provider and inconvenience for the patient of having to periodically collect and refill oxygen cylinders at a remote depot. "Our new BONSAI and OMNI devices demonstrate CHAD's commitment to technology that improves patient care while lowering operating costs for homecare providers," the CEO added. About CHAD Therapeutics CHAD Therapeutics, Inc. develops, manufactures and markets respiratory care devices designed to improve the efficiency of oxygen delivery systems for home health care and hospital treatment of patients suffering from pulmonary diseases. For more information, visit www.CHADtherapeutics.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statements under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The foregoing statements regarding prospects for future earnings and revenues, future sales trends and the introduction of products under development are forward-looking statements that involve certain risks and uncertainties. A number of important factors could cause actual results to differ materially from those contemplated by such forward-looking statements. These include the loss of one or more major customers, increased competition, the introduction of new products with perceived competitive advantages over the Company's products, changes or proposed changes in health care reimbursement which affect home care providers and CHAD's ability to anticipate and respond to technological and economic changes in the home oxygen market. Moreover, the success of the Company's products and products under development will depend on their efficacy, reliability and the health care community's perception of the products' capabilities and benefits, the degree of acceptance the products achieve among homecare providers and, with respect to products under development, obtaining timely regulatory approval. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Company's annual and quarterly reports filed with the Securities and Exchange Commission under the caption "Outlook: Issues and Risks." |
|
|||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion